中文版 | English
题名

Current landscape and future prospects of RET and ROS1 targets

作者
通讯作者Zhang, Hai-Long
发表日期
2023-09-01
DOI
发表期刊
ISSN
2046-8954
EISSN
2046-8962
卷号12期号:3
摘要
RET and ROS1 are becoming key targets for targeted therapy. To show current landscape of ROS1 and RET targets, a patent analysis was performed. The present results indicated that inhibitor structures of ROS1 target demonstrated unique elements compared with inhibitor structures of RET or BRAF targets. Our study was the first time to uncover that a number of inhibitor structures of ROS1 target contained sulfur and boron elements. The inhibitors of RET target could be developed for treatment of various cancers, including lung cancer, thyroid cancer, and other solid tumor, while the inhibitors of ROS1 target are virtually developed for treatment of lung cancer. Our findings provide a new insight for drug discovery of ROS1 and RET target.
关键词
相关链接[来源记录]
收录类别
语种
英语
学校署名
其他
WOS研究方向
Pharmacology & Pharmacy
WOS类目
Pharmacology & Pharmacy
WOS记录号
WOS:001062410400002
出版者
来源库
Web of Science
引用统计
被引频次[WOS]:1
成果类型期刊论文
条目标识符http://sustech.caswiz.com/handle/2SGJ60CL/567785
专题理学院_化学系
作者单位
1.Cent Int Intellectual Property Baotou Co Ltd, Baotou 014030, Peoples R China
2.Southern Univ Sci & Technol, Coll Sci, Dept Chem, Shenzhen 518055, Peoples R China
推荐引用方式
GB/T 7714
Zhang, Hai-Long,Kong, Qian. Current landscape and future prospects of RET and ROS1 targets[J]. PHARMACEUTICAL PATENT ANALYST,2023,12(3).
APA
Zhang, Hai-Long,&Kong, Qian.(2023).Current landscape and future prospects of RET and ROS1 targets.PHARMACEUTICAL PATENT ANALYST,12(3).
MLA
Zhang, Hai-Long,et al."Current landscape and future prospects of RET and ROS1 targets".PHARMACEUTICAL PATENT ANALYST 12.3(2023).
条目包含的文件
条目无相关文件。
个性服务
原文链接
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
导出为Excel格式
导出为Csv格式
Altmetrics Score
谷歌学术
谷歌学术中相似的文章
[Zhang, Hai-Long]的文章
[Kong, Qian]的文章
百度学术
百度学术中相似的文章
[Zhang, Hai-Long]的文章
[Kong, Qian]的文章
必应学术
必应学术中相似的文章
[Zhang, Hai-Long]的文章
[Kong, Qian]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
[发表评论/异议/意见]
暂无评论

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。